Sellar RS, et al. - Researchers sought to assess the treatment and outcome for teenage and young adult (TYA) patients (aged 16–24 years) with acute lymphoblastic leukaemia (ALL) who relapse on contemporary risk-adapted paediatric protocol. They noted inferior outcomes for patients relapsing on active treatment compared to those relapsing after completing treatment. At the end of the study period, no patient with B cell ALL relapsing on treatment was alive. Outcomes thereby suggest that TYA patients with ALL who relapse on the UK paediatric protocol, UKALL2003, are largely unsalvageable with conventional approaches aimed at achieving the second remission followed by allogeneic haematopoietic cell transplant. acute lymphoblastic leukaemia, teenage and young adults, allogeneic transplant, salvage chemotherapy